(NYSEMKT: NSRX) Nasus Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 48.09%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 104.62%.
Nasus Pharma's earnings in 2025 is N/A.On average, 4 Wall Street analysts forecast NSRX's earnings for 2026 to be -$9,098,297, with the lowest NSRX earnings forecast at -$9,271,289, and the highest NSRX earnings forecast at -$8,798,264.
In 2027, NSRX is forecast to generate -$10,844,435 in earnings, with the lowest earnings forecast at -$10,419,163 and the highest earnings forecast at -$11,163,389.